NR3C2 and obesity disorder: Taken together, these data emphasize the therapeutic potential of MR targeting in obesity, a view strengthened by the observations that treatment with steroidal MR antagonists (MRAs) decreases obesity‐associated vascular inflammation, oxidative stress, and arterial stiffening (DeMarco et al., 2015).